Drug Trial Radar · NCT02601885
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: May 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Oct 18, 2016
Primary completion
Apr 20, 2018
Study completion Apr 20, 2018
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 11, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study seeks to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of ABT-555 in participants with relapsing forms of multiple sclerosis (RFMS).
Conditions
- Multiple Sclerosis
Interventions
ABT-555Drug
Intravenous Infusion
PlaceboOther
Intravenous Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and percentage of participants reporting adverse eventsTime frame: Throughout study from Day 1 to Day 176
- Concentration of anti-drug antibody (ADA) titers of ABT-555Time frame: Day 1 to Day 176
- Time to Maximum observed plasma concentration (Tmax) of ABT-555Time frame: Day 1 to Day 176
- Maximum observed plasma concentration (Cmax) of ABT-555Time frame: Day 1 to Day 176
- Area under the concentration curve (AUC) of ABT-555Time frame: Day 1 to Day 176
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Compass Research LLC
Orlando, Florida
Rowe Neurology Institute
Lenexa, Kansas
Parexel International
Baltimore, Maryland
MIND
Farmington Hills, Michigan
Duke Univ Med Ctr
Durham, North Carolina
Tri-State Mountain Neurology
Johnson City, Tennessee
Clinical Trial Network
Houston, Texas
Integrated Neurology Services
Alexandria, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.